Abstract
Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 88-94 |
| Number of pages | 7 |
| Journal | Epilepsy Research |
| Volume | 82 |
| Issue number | 1 |
| DOIs | |
| State | Published - Nov 2008 |
Fingerprint
Keywords
- Placebo-controlled study
- Pregabalin
- Refractory partial epilepsy
- Secondarily generalized tonic-clonic
- Seizure reduction
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin. / Briggs, Deborah E.; Lee, Caroline M.; Spiegel, Katharyn; French, Jacqueline A.
In: Epilepsy Research, Vol. 82, No. 1, 11.2008, p. 88-94.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reduction of secondarily generalized tonic-clonic (SGTC) seizures with pregabalin
AU - Briggs, Deborah E.
AU - Lee, Caroline M.
AU - Spiegel, Katharyn
AU - French, Jacqueline A.
PY - 2008/11
Y1 - 2008/11
N2 - Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.
AB - Purpose: To determine whether pregabalin reduces SGTC seizures in clinically refractory epilepsy. Methods: Design: Post hoc analysis performed on pooled data from three double-blind, placebo-controlled trials of similar design. Participants: Patients with partial seizures who failed ≥2 antiepileptic drugs at maximally tolerated doses. This analysis excluded those who did not have an SGTC seizure during baseline or treatment periods. Outcome measure: Absolute and conditional reduction analyses examined change from baseline in SGTC seizure rates. The absolute reduction analysis used response ratio (RRatio) to compare reduction in seizure-frequency from baseline (B) during a 12-week treatment (T) period [RRatio = ((T - B)/(T + B)) × 100]. The conditional analysis examined proportional risk of having SGTC seizure if a partial seizure had occurred. Results: Of 1052 intent-to-treat patients, 409 were included. Sixteen were seizure-free during treatment and not included in the conditional analysis. A significant reduction in absolute SGTC seizures from baseline was observed in patients receiving pregabalin 600 mg/day (treatment RRatio, -33 versus placebo, -3.7; P = 0.0005). A lower dose of pregabalin (300 mg/day), administered in one study, demonstrated a trend (nonsignificant) toward reduced SGTC seizures (treatment, -24.7 versus placebo, -10.0; P = 0.2493). Conclusion: As adjunctive therapy, pregabalin 600 mg/day is effective in reducing the absolute frequency of SGTC seizures in patients with refractory partial epilepsy, but not secondary generalization.
KW - Placebo-controlled study
KW - Pregabalin
KW - Refractory partial epilepsy
KW - Secondarily generalized tonic-clonic
KW - Seizure reduction
UR - http://www.scopus.com/inward/record.url?scp=55649083718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55649083718&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2008.07.004
DO - 10.1016/j.eplepsyres.2008.07.004
M3 - Article
VL - 82
SP - 88
EP - 94
JO - Epilepsy Research
JF - Epilepsy Research
SN - 0920-1211
IS - 1
ER -